Drug Trial Radar · NCT00003835
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
Last checked: Nov 19, 2026Latest source record: Oct 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,260
Planned (sponsor's estimate)
Start
May 1999
Primary completion
Aug 2007
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- SWOG Cancer Research Network; North Central Cancer Treatment Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
- First posted
- Apr 27, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for stage III colon cancer. Randomized phase III trial to compare the effectiveness of fluorouracil plus leucovorin with or without irinotecan in treating patients who have undergone surgery for stage III colon cancer.
Conditions
- Adenocarcinoma of the Colon
- Stage III Colon Cancer
Interventions
leucovorin calciumDrug
Given IV
fluorouracilDrug
Given IV
irinotecan hydrochlorideDrug
Given IV
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to recurrenceTime frame: From time of resection until documented disease progression, assessed up to 6 years
- SurvivalTime frame: Up to 6 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer and Leukemia Group B
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.